Trials / Completed

CompletedNCT01179529

Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair®) Treatment in Atopic Dermatitis

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: —

Sponsor: Technical University of Munich · Academic / Other
Sex: All
Age: 18 Years – 70 Years
Healthy volunteers: Not accepted

Summary

This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.

Conditions

Atopic Dermatitis
Atopic Eczema

Interventions

Type	Name	Description
DRUG	Omalizumab (Xolair®)

Timeline

First posted: 2010-08-11
Last updated: 2012-01-10

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01179529. Inclusion in this directory is not an endorsement.